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habdomyosarcoma (RMS), the most common pe-
diatric soft-tissue sarcoma, has two major histo-
logical subtypes: embryonal RMS (ERMS), which
has a favorable prognosis, and alveolar RMS (ARMS),
which has a poor outcome. Although both forms of RMS
express muscle cell–speciﬁc markers, only ARMS cells
express PAX3-FOXO1a or PAX7-FOXO1a chimeric pro-
teins. In mice, Pax3 and Pax7 play key roles in muscle
cell development and differentiation, and FoxO1a regu-
lates myoblast differentiation and fusion; thus, the aber-
rant regulation of these proteins may contribute to the
development of ARMS. In this paper, we report that
R
 
FOXO1a is not expressed in primary ARMS tumors or
ARMS-derived tumor cell lines and that restoration of
FOXO1a expression in ARMS cells is sufﬁcient to induce
cell cycle arrest and apoptosis. Strikingly, the effects
of FOXO1a are selective, as enforced expression of
FOXO1a in ERMS-derived tumor cell lines had no ef-
fect. Furthermore, FOXO1a induced apoptosis in ARMS
by directly activating the transcription of 
 
caspase-3
 
. We
conclude that FOXO1a is a potent and speciﬁc tumor
suppressor in ARMS, suggesting that agents that restore
or augment FOXO1a activity may be effective as ARMS
therapeutics.
 
Introduction
 
Rhabdomyosarcoma (RMS) is the most common soft-tissue sar-
coma of childhood. The two most common histological subtypes
are embryonal RMS (ERMS) and alveolar RMS (ARMS). Al-
though recent progress in treatment has improved the outcome of
patients with ERMS, those with ARMS often relapse with highly
metastatic tumors (J. Anderson et al., 2001). Primary ARMS is
characterized by a high apoptotic index and responsiveness to
radiotherapy and chemotherapy (J. Anderson et al., 2001), yet
relapsed ARMS acquires mutations in the p53 pathway, which
renders these tumors resistant to therapy (Taylor et al., 2000).
ARMS cells display morphological features consistent
with poorly differentiated skeletal muscle cells and typically ex-
press the muscle cell–specific transcription factor myogenin
(Dias et al., 2000). ARMS is characterized by the recurrent chro-
mosome translocations t(2;13) or t(1;13) that encode the chi-
meric transcription factors PAX3-FOXO1a and PAX7-FOXO1a,
respectively (Barr, 2001). In mice, Pax3 is essential for primary
myoblast cell migration during embryogenesis (Epstein et al.,
1995; Conway et al., 1997), whereas Pax7 is required for the
specification of muscle satellite cells (Seale et al., 2000). Thus,
alterations of the PAX gene function by PAX3-FOXO1a and
PAX7-FOXO1a are thought to contribute to muscle cell trans-
formation. In accordance with this notion, PAX3-FOXO1
functions as an oncogene in immortal NIH-3T3 fibroblast cells
(Fredericks et al., 1995; Lam et al., 1999). However, enforced
expression of Pax3-FOXO1a in mice is not sufficient to cause
ARMS (M. Anderson et al., 2001; Lagutina et al., 2002), and in
a Myf6 promoter-driven conditional 
 
Pax3-Fkhr
 
 knock-in mouse
model, ARMS-like tumors are an extremely rare event, although
they occur in 
 
 
 
20% of these mice when they are crossed onto an
Ink4a/Arf- or p53-deficient background (Keller et al., 2004).
The FOXO family of transcription factors (FOXO1a,
FOXO3, and FOXO4a) regulates diverse cellular responses, in-
cluding apoptosis, cell cycle arrest, differentiation, DNA repair,
and/or oxidative stress (Burgering and Kops, 2002; Birkenkamp
and Coffer, 2003; Bois and Grosveld, 2003; Tran et al., 2003;
Accili and Arden, 2004). How FOXO proteins direct such di-
verse processes is largely unknown, but some of the cellular
alterations associated with skeletal muscle differentiation are
similar to those typical of apoptosis. For example, remodeling
 
Correspondence to Gerard C. Grosveld: gerard.grosveld@stjude.org
Abbreviations used in this paper: ARMS, alveolar RMS; Casp, caspase-3; ChIP,
chromatin immunoprecipitation;
 
 
 
ER, estrogen receptor; ERMS, embryonal RMS;
FOXO1a-TM, dominant-active FOXO1a; FOXO1a-TM-ER
 
TAM
 
, tamoxifen-regulated
form of FOXO1a-TM; FOXO1a-WT, wild-type FOXO1a; MyoHC, myosin
heavy chain; RMS, rhabdomyosarcoma; SEAP, secreted alkaline phosphatase. 
JCB • VOLUME 170 • NUMBER 6 • 2005 904
 
of the cytoskeleton (Qu et al., 1997; Gallo et al., 1999; Hall and
Nobes, 2000; Sabourin and Rudnicki, 2000; Coleman and Ol-
son, 2002) and activation of 
 
Casp3
 
, a key effector of apoptotic
protease (Fernando et al., 2002), are common features of both
processes. Furthermore, FoxO1a appears to play a role as a mas-
ter regulator of muscle cell differentiation in mice (Bois and
Grosveld, 2003; Nishiyama et al., 2004; Bois et al., 2005), as
augmenting FoxO1a activity provokes an overfused phenotype,
whereas disrupting FoxO1a function is sufficient to prevent
myoblast cell fusion (Bois and Grosveld, 2003). Furthermore,
the induction of myoblast differentiation triggers the nuclear
translocation and accumulation of FoxO1a and leads to the ex-
pression of a cadre of target genes necessary for cytoskeleton
remodeling and cell fusion (Bois and Grosveld, 2003).
The t(2;13) or t(1;13) in ARMS results in a haploid gene
dose of human FOXO1a and, given the profound effects of
FoxO1a on muscle cell fate, we reasoned that reductions in
FOXO1a may play a role in alveolar rhabdomyosarcomagenesis.
Indeed, here we report that FOXO1a expression is repressed in
ARMS and that this occurs through both transcriptional and post-
translational mechanisms. In addition, FOXO1a has been shown to
function as a selective tumor suppressor for ARMS but not ERMS
tumors in vivo. Finally, the tumor suppressor functions of FOXO1a
are also linked to its ability to regulate the transcription of 
 
Casp3
 
.
 
Results
 
Loss of FOXO1a expression is a hallmark 
of ARMS but not ERMS
 
To address whether the expression of FOXO family proteins
(FOXO1a, FOXO3a, and FOXO4) was maintained in pediatric
RMS, we immunoblotted cell lysates of frozen primary ARMS
and ERMS tumor biopsies (from the tumor bank at St. Jude
Children’s Research Hospital, Memphis, TN) using antibodies
specific for FOXO1a, FOXO3a, and FOXO4. In addition, we
determined the expression of these proteins in four ERMS
(Rh2, Rh6, RD, and JR1) and four ARMS (Rh3, Rh4, Rh30,
and Rh41) tumor-derived cell lines, which are models for sec-
ondary RMS. Strikingly, FOXO family proteins were undetect-
able in primary ARMS, whereas at least one FOXO member
was expressed at high levels in all primary ERMS (Fig. 1 A).
Analysis of ERMS- and ARMS-derived cell lines confirmed
that all ERMS cells showed robust expression of FOXO1a,
FOXO3a, and/or FOXO4, whereas FOXO1a was only weakly
expressed in one ARMS cell line (Fig. 1 A, Rh4 cells).
FoxO1a activity is essential for muscle cell fusion that
accompanies terminal differentiation of muscle cell progeni-
tors (Bois and Grosveld, 2003; Bois et al., 2005). To assess
whether differences in the expression of FOXO proteins in
ARMS versus ERMS might reflect differences in their state of
differentiation, we also evaluated the expression of two mus-
cle cell–specific markers, myogenin (intermediate differentia-
tion) and myosin heavy chain (MyoHC; late differentiation).
Interestingly, ARMS tumors and cell lines often expressed the
intermediate differentiation marker myogenin, whereas most
ERMS tumors and cell lines also expressed the late differenti-
ation marker MyoHC (Fig. 1 A). Thus, ARMS tumors are
more myoblast-like in their differentiation status than are
ERMS tumors.
To determine whether alterations in the expression of
FOXO proteins accompany muscle cell fusion and differenti-
ation, we used C2C12 cells, which like normal myoblasts,
Figure 1. FOXO proteins are not expressed in ARMS. (A)
Immunoblot analyses of FOXO1a, FOXO3a, and FOXO4
proteins were determined in samples of primary ARMS (t[2;13]
only) and ERMS tumors. The expression of these proteins was
also evaluated in cell lines derived from ERMS (Rh2, Rh6,
JR1, and RD) and ARMS (Rh3, Rh4, Rh30, and Rh41; t[2;13]
only) tumors. The expression of the muscle cell–specific mark-
ers myogenin and MyoHC is also shown. FOXO proteins
were not expressed in ARMS tumors and in all but one
ARMS-derived cell line; however, all FOXO proteins were ex-
pressed in ERMS tumors and cell lines. Fast Green dye was
used to confirm equal loading and homogeneous protein
transfer. (B) A Western blot analysis of the indicated proteins
in differentiating C2C12 cells, over a 3-d time period, is
shown. Uniform protein loading and homogenous transfer of
SDS-PAGE gels were confirmed by staining transferred
membranes with Fast Green. 
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undergo differentiation and fuse into myotubes after being
transferred to a low serum medium (Rando and Blau, 1994). As
expected, these cells first expressed the intermediate marker
myogenin at a time when cell fusions began, and then ex-
pressed high levels of MyoHC as the cells terminally differen-
tiated (Fig. 1 B). The FoxO family members FoxO3a and
FoxO4 were not expressed at any interval during differentiation
of C2C12 cells. In contrast, FoxO1a expression was detectable
in proliferating muscle cell progenitors, and as expected (Bois
and Grosveld, 2003), the levels of FoxO1a were induced after
the receipt of differentiation cues (Fig. 1 B). However, by day 3
of culture, FoxO1a levels began to rapidly diminish such that
the protein was not expressed in differentiated muscle cells (Fig.
1 B). These findings underscore the dynamic regulation and role
for FoxO1a in orchestrating muscle cell fusion (Bois and Gros-
veld, 2003; Bois et al., 2005) and suggest that loss of FOXO1a
expression in ARMS would disable the ability of these tumor
cells to fuse and/or terminally differentiate.
In many systems the activity of FOXO1a is held in
check by AKT-mediated phosphorylations (of FOXO1a-
Thr24, -Ser256, and -Ser319) that target the protein for nuclear
export to the cytoplasm, where it is degraded by the proteasome
(Brunet et al., 1999; Matsuzaki et al., 2003). To address whether
there were changes in the localization of FOXO1a in ARMS
versus ERMS, we performed immunofluorescence assays in the
panel of ERMS and ARMS cell lines and transduced these cells
with retroviruses that express wild-type FOXO1a (FOXO1a-
WT) or dominant-active FOXO1a (FOXO1a-TM) that bears
alanine substitution mutations in the three AKT phosphory-
lation sites (Brunet et al., 1999). Although the endogenous
FOXO1a protein could not be detected in any of the cells with
the FOXO1a-specific antibody by immunofluorescence assays,
the overexpressed FOXO1a-WT and FOXO1a-TM proteins
were readily evident in all transduced cells with the FOXO1a-
specific antibody (Fig. 2). Furthermore, both FOXO1a-WT and
FOXO1a-TM proteins were nuclear in their localization, indi-
cating that nuclear-to-cytoplasmic export is not necessarily aug-
mented in ARMS. Interestingly, however, overexpression of
both FOXO1a-WT and FOXO1a-TM led to rapid and distinct
morphological changes in ARMS, but not ERMS, cells. Specifi-
cally, Rh3, Rh4, and RH41 FOXO1a-expressing cells showed
evidence of cell shrinkage, whereas Rh30-transduced cells took
on an elongated appearance (Fig. 2), indicating that FOXO1a
specifically alters the biology of ARMS cells.
FOXO proteins function as potent activators of their tran-
scription targets (Bois and Grosveld, 2003; Accili and Arden,
2004; Bois et al., 2005), suggesting that FOXO1a’s function
as a transcription factor might be compromised in ARMS
cells. To evaluate FOXO transcriptional activity in ERMS and
ARMS tumor cells, we transiently transfected them with a lu-
ciferase promoter–reporter harboring six FOXO binding sites,
which is responsive to FOXO1a activity (Furuyama et al.,
2000). As expected from their expression of FOXO proteins,
JR1 and RD ERMS cells displayed higher levels of basal activ-
ity of this reporter than did ARMS cells. Specifically, on an ab-
solute scale, JR1 and RD ERMS cells showed basal values of
luciferase activity of 150 and 25, respectively, whereas basal
luciferase activities of Rh3, Rh4, Rh30, and RH41 cells were
1.2, 2.4, 9.9, and 14.7, respectively (Fig. 3, A and B). Further-
more, when cotransfected with a FOXO1a expression construct,
ERMS cells showed a marked induction of the FOXO-responsive
reporter (of 28- and 5-fold for JR1 and RD cells, respectively),
whereas this response was diminished in all four ARMS tumor
cell lines (with a range of 1.4- to 2.8-fold; Fig. 3, A and B).
Therefore, FOXO1a transcriptional activity is also diminished
in ARMS cells.
Figure 2. FOXO1a localization in ARMS and ERMS. Endogenous
levels of FOXO1a were not detectable in RMS cells by immuno-
fluorescence with the FOXO1a-specific antibody ( FOXO1a),
but enforced expression of FOXO1a-WT or FOXO1a-TM demon-
strated nuclear localization of FOXO1a in ARMS and ERMS.
Note the nuclear shrinkage, a hallmark of apoptosis, in Rh3,
Rh4, and Rh41 ARMS cells overexpressing FOXO1a or
FOXO1a-TM proteins, as well as elongation of Rh30 cells ex-
pressing FOXO1a. In contrast, the two ERMS cell lines show little
change in their morphology after overexpression of FOXO1a.
DAPI staining was used to stain DNA. Bar, 50  m. 
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To address the potential mechanism by which FOXO1a
protein expression was suppressed in ARMS, we initially com-
pared levels of FOXO1a transcripts in ERMS and ARMS cells
by quantitative real-time RT-PCR. Indeed, ARMS cell lines
expressed greatly reduced levels of 
 
FOXO1a
 
 transcripts com-
pared with levels of 
 
FOXO1a
 
 mRNA present in ERMS cells
(Fig. 4 A). Further, levels of 
 
FOXO1a
 
 transcripts in ARMS
were much less than one would expect from the reductions of
just a haploid gene dose of 
 
FOXO1a
 
 attributable to the 
 
PAX3
 
-
 
FOXO1a
 
 translocation present in these tumors. Therefore, re-
ductions in FOXO1a expression in ARMS are at least in part
the result of reduced levels of 
 
FOXO1a
 
 transcription and/or a
reduced half-life of 
 
FOXO1a
 
 mRNA.
The reductions in the FOXO1a protein in ARMS were
much more profound than the reductions in FOXO1a transcripts
observed in these tumor cells. This suggested that pathways
that regulate FOXO1a protein levels might be operational in
ARMS. In particular, the PI3K–AKT pathway phosphorylates
FOXO1a and targets the protein for destruction by the protea-
some (Matsuzaki et al., 2003), and recent studies have suggested
that AKT targets FOXO1a for degradation in ARMS-derived
cell lines (Wan and Helman, 2003). Hallmarks of this pathway
are activating phosphorylations of AKT; however, immunoblot
analyses of its phosphorylation status, using antibodies specific
for the phospho-Thr
 
308
 
 or phospho-Ser
 
473
 
 forms of AKT, dem-
onstrated that AKT was not active in ARMS or ERMS cells, al-
though active AKT was readily observed in cells lacking PTEN
(phosphate and tension homologue), a negative regulator of
this pathway (Fig. 4 B). Therefore, loss of FOXO1a protein in
ARMS appears independent of AKT.
FOXO transcription factors are degraded by the pro-
teasome (Matsuzaki et al., 2003). Therefore, we addressed
whether loss of FOXO1a in ARMS could be the result of in-
creased degradation by the proteasome by treating these cells
with the proteasome inhibitor MG132. Indeed, immunoblot
analyses demonstrated that ARMS cells treated with MG132
showed a rapid and robust up-regulation of the FOXO1a pro-
tein (Fig. 4 C). Therefore, reductions in the FOXO1a protein in
ARMS are at least in part attributable to high rates of protea-
some-mediated turnover, and loss of FOXO1a in ARMS is the
result of pathways that affect the transcription or half-life of
FOXO1a mRNA and a posttranslational pathway that provokes
rapid degradation of the protein.
 
FOXO1a induces G
 
2
 
/M cell cycle arrest, 
morphological changes, and apoptosis 
in ARMS
 
The finding that FOXO1a expression is markedly reduced in
ARMS suggested that loss of the FOXO1a protein might be a
crucial event in the etiology of this malignancy. To address the
potential biological effects of FOXO1a, we transduced the
ARMS and ERMS cell lines with retroviruses expressing
FOXO1a-WT (MSCV-FOXO1a) or the AKT-unphosphory-
latable, dominant-active mutant of FOXO1a-TM (MSCV-
Figure 3. FOXO1a transcriptional activity is impaired in ARMS. (A)
Transcriptional activity of FOXO1a was analyzed in JR1 and RD ERMS
cells. The pGL3 basic luciferase reporter showed little activity with (light
gray bars) or without (white bars) exogenous FOXO1a-WT. However, a re-
porter construct containing six FOXO DNA binding sites (dark gray bars)
was robustly induced by FOXO1a-WT (black bars). (B) In contrast, ARMS
cell lines show little induction in absolute luciferase activity by FOXO1a-WT.
Note the much lower absolute luciferase activity scale in ARMS than in
ERMS. Values are the means of at least triplicate samples, and error bars
depict the standard deviation. All values were normalized using  -actin
promoter–driven SEAP as a transfection efficiency control. Fold increases
between the reporter construct containing six FOXO DNA binding sites
expressing exogenous FOXO1a-WT versus empty vector are indicated.
Figure 4. Suppression of FOXO1a expression in ARMS. (A)
Real-time RT-PCR analysis of FOXO1a transcripts in ERMS and
ARMS cell lines demonstrated that FOXO1a is suppressed in
ARMS, and at levels below what one would expect from a hap-
loid gene dose of FOXO1a. Relative levels of FOXO1a tran-
scripts were normalized to those of glyceraldehyde-3-phosphate
dehydrogenase transcripts using an arbitrary unit of measure.
Values are the means of triplicate samples, and error bars depict
variations between samples. (B) Immunoblot analyses revealed
that high levels of AKT are expressed in ARMS and ERMS cells.
However, AKT is inactive when compared with a PTEN knock-out
cell line control, as indicated by the lack of phosphorylated AKT
(P-AKT
Thr308 and P-AKT
Ser473). Equal loading and homogeneous
protein transfer were confirmed by staining blots with Fast
Green dye. (C) FOXO1a protein is suppressed in ARMS
through a proteasome-dependent pathway. The indicated
ARMS cells were treated for 8 h with the proteasome inhibitor
MG132, and endogenous levels of FOXO1a were determined
by immunoblot analyses. 
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FOXO1a-TM). We reasoned that because the AKT pathway
was inactive in ARMS cells (Fig. 4 B), enforced expression of
FOXO1a-TM would have effects similar to those caused by
overexpression of FOXO1a-WT. Strikingly, enforced expres-
sion of either FOXO1a or FOXO1a-TM induced rapid apopto-
sis in Rh3, Rh4, and Rh41 cells (but not in Rh30 ARMS cells;
Fig. 5 B) as well as G
 
2
 
/M cell cycle arrest in all four ARMS
cell lines (Fig. 6 A). By contrast, the deleterious effects of
FOXO1a on cell growth and survival were restricted to ARMS,
as ERMS cells were totally unaffected by enforced expression
of FOXO1a or FOXO1a-TM (Fig. 5 B and Fig. 6, A and B).
Furthermore, FOXO1a-expressing Rh4 cells, and especially
Rh30 cells, displayed morphological changes reminiscent of
muscle cell differentiation before undergoing apoptosis, as
cells assumed elongated shapes and aligned in a manner akin
to that of differentiating primary myoblasts (data shown for
FOXO1a-TM–expressing cells; Fig. 6 C). However, only par-
tial morphological changes were observed, as these cells did
not contract or express the late differentiation marker MyoHC
(unpublished data).
 
FOXO1a directly regulates the 
transcription of 
 
Casp3
 
Given FOXO1a’s role as a master regulator of primary myo-
blast differentiation (Bois and Grosveld, 2003; Bois et al.,
2005) and its ability to provoke apoptosis in ARMS (Fig. 5 B),
we reasoned that the loss of FOXO1a expression in ARMS
might alter the expression of components of the differentiation
program of muscle cells and/or cells that are involved in apop-
tosis. 
 
Casp3
 
 was an attractive candidate for such a target, es-
pecially given its role as an effector protease in apoptosis and
its essential role in initiating skeletal myogenic differentiation
(Fernando et al., 2002). To determine whether the biological
effects of enforced FOXO1a expression in ARMS were asso-
ciated with 
 
Casp3
 
 expression and/or activity, we assessed its
regulation in FOXO1a-TM–expressing ARMS and ERMS
cells. Notably, all cells overexpressing FOXO1a-TM, regard-
less of their origin, displayed substantial increases in the level
of 
 
Casp3
 
 mRNA (Fig. 7 A). To determine if this induction was
also reflected at the level of the protein, we assessed levels of
pro-Casp3 and activated Casp3 (p17 and p20), by immunoblot
of FOXO1a-TM–expressing ARMS and ERMS (Fig. 7 B), as
well as overall Casp3 activity (Fig. 7 C). Interestingly, levels
of pro-Casp3 and activated Casp3 proteins were only elevated
in ARMS cells that were sensitive to FOXO1a-induced apop-
tosis (Fig. 7, B and C). Therefore, some level of translational
control of Casp3 appears to be operational in ERMS cells and
in Rh30 ARMS cells, which prevents excessive production of
the Casp3 protein.
FOXO proteins activate transcription by binding consen-
sus TTGTTTAC elements in the regulatory regions of their tar-
get genes (Furuyama et al., 2000). Interestingly, two regions of
 
 
 
500 bp (
 
 
 
3.8/
 
 
 
3.3 and 
 
 
 
1.0/
 
 
 
1.5 kb) in the promoter-regula-
tory region of the mouse 
 
Casp3
 
 gene harbor several TTGTTTAC
elements. These sites are also present in the human 
 
CASP3
 
 and
Fugu 
 
Casp3
 
 promoter-regulatory regions (unpublished data).
We therefore addressed whether FOXO1a occupies these ele-
ments in mouse myoblasts undergoing differentiation using
chromatin immunoprecipitation (ChIP) analyses. Because of
the  poor immunoprecipitation using the polyclonal FOXO1a
antibody, we had to address this issue using FLAG-tagged
FOXO1a. Primary myoblasts transduced with a retrovirus ex-
pressing FLAG-FOXO1a (MSCV-FOXO1a) were selected by
FACS for GFP, which is expressed in cis by virtue of an IRES
in this vector; enforced expression of FoxO1a-WT using these
conditions has limited, if any, effects on the differentiation pro-
gram of primary myoblasts (Bois and Grosveld, 2003). A ChIP
analysis demonstrated that FOXO1a was recruited to these sites
in the 
 
Casp3
 
 promoter within 6 h of the induction of differentia-
tion (Fig. 8 A). Furthermore, the activity of luciferase pro-
moter–reporter constructs containing either of these elements
Figure 5. Restoration of FOXO1a expression in ARMS cells induces
apoptosis. (A) A FACS analysis of GFP control and FOXO1a-IRES-GFP–
transduced ERMS and ARMS cell lines. The fine line shows nontransduced
negative control cells, the dashed line displays GFP-only transduced cells,
and the bold line indicates FOXO1a-IRES-GFP–transduced cells. The identity
and percentages of GFP- and FOXO1a-IRES-GFP–positive cells is given for
each cell line. Note the low percentage of FOXO1a-positive Rh3 cells,
which is attributable to their rapid death. Only JR1 and RD ERMS lines could
be FACS sorted for FOXO1a-IRES-GFP and expanded in culture, whereas all
the FOXO1a-IRES-GFP–transduced ARMS cells either died (Rh3, Rh4, and
Rh41) or failed to expand (Rh30). (B) The apoptotic index of ERMS and
ARMS cells engineered to express FOXO1a (gray bars), FOXO1a-TM (black
bars), or vector alone (white bars) was augmented in ARMS cells expressing
FOXO1a, whereas the apoptotic index of ERMS cells expressing FOXO1a
was unaffected. No significant differences were observed between ARMS or
ERMS cells overexpressing FOXO1a-WT versus FOXO1a-TM. Values are the
means of triplicate samples, and error bars depict SD. 
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in the 
 
Casp3
 
 gene was dramatically induced in C2C12 mus-
cle cells after the receipt of differentiation cues, and this re-
sponse was augmented in myoblasts engineered to overexpress
FOXO1a (Fig. 8, B and C). By contrast, luciferase promoter–
reporters  bearing deletions of the TTGTTTAC elements in
these regions of the 
 
Casp3
 
 promoter were not responsive to dif-
ferentiation cues or to FOXO1a (Fig. 8, B and C). Therefore,
FOXO1a is recruited to FoxO-binding sites at the 
 
Casp3
 
 locus
during the initial phase of myoblast differentiation, which coin-
cides with the induction of Casp3 activity in differentiating pri-
mary myoblasts (Fernando et al., 2002). Collectively, these data
support the conclusion that FOXO1a’s ability to initiate apopto-
sis and differentiation in ARMS cells appears strongly linked to
its ability to directly activate caspase-3 transcription.
 
FOXO1a is a tumor suppressor in ARMS
 
The ability of FOXO1a to selectively compromise the growth
and/or survival of ARMS tumor cells suggested that loss of
FOXO1a expression might be essential for tumorigenesis. To
test this hypothesis, we transduced Rh30 cells with a vector ex-
pressing a tamoxifen-regulated form of FOXO1a-TM (FOXO1a-
TM-ER
 
TAM
 
), in which FOXO1a-TM was fused in-frame with the
hormone-binding domain of an estrogen receptor (ER) that has
been engineered to selectively bind to the ER agonist tamoxifen
(Mahfoudi et al., 1995). Attempts to establish other ARMS
FOXO1a-TM-ER
 
TAM
 
–expressing cell lines (Rh3, Rh4, and
Rh41) failed because of the leakiness of the ER
 
TAM
 
 system and
their greater sensitivity to FOXO1a-induced apoptosis (Fig. 5).
As expected for the effects of enforced expression of FOXO1a-
TM in Rh30 ARMS cells (Fig. 6), tamoxifen treatment of Rh30
cells expressing FOXO1a-TM-ER
 
TAM
 
 induced G
 
2
 
/M cell cycle
arrest and dramatic changes in cell morphology (Fig. 9, A and B).
In contrast, tamoxifen treatment had no detectable effect on
Rh30 cells expressing only the retroviral vector.
Tamoxifen-treated Rh30 cells expressing FOXO1a-
TM-ER
 
TAM
 
 remained elongated and arrested for up to 20 d in
culture. Once elongated, this change was irreversible; i.e., the
removal of tamoxifen did not release FOXO1a-TM-ER
 
TAM
 
–
expressing cells from cell cycle arrest (unpublished data).
However, after 20 d in culture, colonies that rapidly overtook
the culture began to appear, and immunoblotting analysis re-
vealed that these cells had failed to express FOXO1a-TM-
ER
 
TAM
 
 (Fig. 9 C), underscoring the essential selection for loss
of FOXO1a in ARMS.
To test the effects of enforced FOXO1a expression on the
tumorigenicity of Rh30 cells, we injected male NOD/SCID
mice with 5 
 
  
 
10
 
6
 
 Rh30 cells transduced with either the retro-
viral vector alone (Rh30 vector; 
 
n 
 
  
 
4) or a retrovirus harbor-
ing FOXO1a-TM-ER
 
TAM
 
 (Rh30-FOXO1a-TM-ER
 
TAM
 
; 
 
n 
 
  
 
8).
Within 5 wk, the average diameter of tumors arising from the
Rh30-vector cells was 22 mm (range 20–24 mm), whereas that
of tumors arising from Rh30-FOXO1a-TM-ER
 
TAM
 
 cells was
Figure 6. FOXO1a selectively induces G2/M cell cycle arrest
in ARMS cells. (A) FOXO1a (gray bars) and FOXO1a-TM
(black bars) expression induced G2/M phase cell cycle arrest
in ARMS cells. Vector-only expressing ARMS cells are de-
noted by white bars. No cycle arrest was observed in ERMS
lines. Values are the means of triplicate samples, and error
bars depict variations between samples. (B) No morphologi-
cal changes were observed in the JR1 and RD ERMS cell lines
expressing FOXO1a-TM. GFP expression was overlaid to
confirm that the cells had been transduced. Identical results
were obtained with FoxO1a-WT (not depicted). (C) Typical
morphological changes induced by FOXO1a in Rh4 and
Rh30 ARMS cells are shown. Note the alignment of cells and
the presence of multinucleated cells in the Rh30 cells express-
ing FOXO1a-TM. Rh3, Rh4, and Rh41 all undergo rampant
apoptosis after FOXO1a-TM expression. GFP expression was
overlaid to confirm that the cells had been transduced and
expressed the MSCV-FOXO1a-TM-IRES-GFP retroviral vector.
Identical pictograms were obtained with FoxO1a-WT (not
depicted). Bars, 50  m. 
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12.5 mm (range 9–17 mm). The smaller tumors arising from
Rh30-FOXO1a-TM-ER
 
TAM
 
 cells reflected their reduced rates
of proliferation (Fig. 9 A), again most likely because of the
leakiness of the ER
 
TAM
 
 system.
To assess whether loss of FOXO1a function was nec-
essary to maintain Rh30 xenografts, mice bearing estab-
lished (5-wk) tumors derived from Rh30-vector cells or Rh30-
FOXO1a-TM-ER
 
TAM
 
 cells were injected daily with 0.1 mg of
tamoxifen citrate. After 1 wk of treatment the percentages of
tumor cells in the S phase in vivo was determined by BrdU in-
corporation. Strikingly, the percentage of Rh30-FOXO1a-TM-
ER
 
TAM
 
 tumor cells in S phase (5%) was substantially lower
than that of cells in Rh30-vector tumors (Fig. 9, D and E, 40
and 50%). The remaining mice were then treated with a higher
daily dose of tamoxifen citrate (0.6 mg) for 9 d. Within this
short interval there was a 50% reduction in overall tumor
size in mice bearing Rh30-FOXO1a-TM-ER
 
TAM
 
–derived xe-
nografts, and two of five tumors regressed completely (Fig.
10 A). By contrast, this treatment failed to affect the growth
of xenografts in mice bearing Rh30-vector cells; indeed, these
tumors grew by more than 50% during the same interval.
Figure 7. FOXO1a activates caspase-3  transcription in RMS, but
caspase-3 is only activated in ARMS. (A) A real-time RT-PCR analysis of
caspase-3 transcripts in ERMS and ARMS cell lines in the absence or pres-
ence of FOXO1a-TM. Transcript levels were normalized to those of glycer-
aldehyde-3-phosphate dehydrogenase mRNA transcripts using an arbi-
trary unit of measure. Fold increases between GFP control–transduced
(white bars) and FOXO1a-TM–transduced cells (black bars) are indicated.
Values are the means of triplicate samples, and error bars depict varia-
tions between samples. (B) The indicated ARMS and ERMS cells were
transduced with the control virus (MSCV-IRES-GFP) or a virus expressing
FOXO1a-TM (MSCV-FOXO1a-TM-IRES-GFP). After 24–72 h, the levels of
FOXO1a, total pro-Casp3 (Casp3), activated Casp3 (p20 and p17), and
actin were assessed in cell extracts by immunoblot. Only low levels of
FOXO1a-TM were detectable in Rh3 and Rh41 cells because of the rapid
apoptosis of these cells, as indicated by high levels of activated Casp3.
(C) Casp3 activity was assessed in the indicated cells 24 (Rh3 and Rh41
cells) or 72 h (Rh4, Rh30, RD, and JR1 cells) after transduction with the
control virus (GFP only) or a virus expressing FOXO1a-TM. Caspase-3 ac-
tivity was normalized to protein content, and fold increases in caspase-3
activity between GFP-only control (white bars) and FOXO1a-TM–trans-
duced cells (black bars) are indicated using an arbitrary unit of measure.
Values are the means of triplicate samples, and error bars depict variations
between samples.
Figure 8. FOXO1a directly binds the Casp3 promoter region upon primary
myoblast differentiation. (A) Direct binding of FLAG-FOXO1a to Casp3
promoter/enhancer regions in transduced mouse primary myoblasts as as-
sessed by ChIP assay. As cells differentiated, FOXO1a showed rapid bind-
ing to the Casp3 promoter/enhancer regions at  3.8/ 3.3 and 11.0/
11.5 kb, which contain FOXO1a binding sites. Cells transduced with an
empty MSCV-IRES-GFP vector were used as a negative control. (B) The in-
duction of differentiation of C2C12 cells increased promoter–reporter lu-
ciferase activity of constructs containing the FoxO1a binding regions at
 3.8/ 3.3 kb upstream of the 5  UTR of mouse Casp3. C2C12 cells
were transiently transfected with the Casp3  3.8/ 3.3 kb luciferase con-
struct alone (closed circles), with wild-type FOXO1a-WT (open circles), with
the dominant-negative FOXO1a TA (closed squares), or with the  3.8/
 3.3 kb promoter region deleted for the FOXO binding sites (open
squares), and differentiation was then induced. Values are the means of
triplicate samples, and error bars depict variations between samples. (C)
Identical to B but with a reporter construct containing the FoxO1a binding
regions at  1.0/ 1.5 kb downstream of the 5  UTR of mouse Casp3.
Note the 10-fold higher induction of this reporter construct compared with
that of the construct in B.JCB • VOLUME 170 • NUMBER 6 • 2005 910
The tamoxifen-dependent reduction in volume of Rh30-
FOXO1a-TM-ER
TAM tumors suggested that FOXO1a induced
apoptosis in these cells in vivo. Indeed, TUNEL analysis
showed that 20% of the cells in Rh30-FOXO1a-TM-ER
TAM tu-
mors were TUNEL positive after tamoxifen treatment, whereas
less than 1% of the cells in the Rh30-vector tumors were
TUNEL positive (Fig. 10, B and C). To confirm that cell death
was caused by apoptosis, indirect immunofluorescence assays
using an antibody specific for active Casp3 was performed
(Fig. 10, D and E). Again,  20% of the Rh30-FOXO1a-TM-
ER
TAM tumor cells were positive for activated Casp3, whereas
active Casp3 was not detected in Rh30-vector tumor cells.
Discussion
The findings reported herein establish that FOXO1a expression
is suppressed in ARMS and that this transcription factor func-
tions as a potent tumor suppressor when reintroduced in ARMS
tumor cells. Interestingly, ERMS cells are insensitive to the tu-
mor suppressor effects of FOXO1a, a finding that underscores
Figure 9. FOXO1a induces cell cycle arrest in ARMS Rh30 cells. (A) Rh30
cells expressing vector alone (circles) or FOXO1a-TM-ER
TAM (triangles) were
treated with tamoxifen (4OH; filled symbols) for the indicated intervals. The
cell cycle profiles showed that 4OH treatment arrested ARMS cells express-
ing the FOXO1a-TM vector; the growth of the cells that expressed vector
alone was not affected. Values are the means of triplicate samples, and er-
ror bars depict variations between samples. (B) Representative morphologi-
cal changes observed in Rh30 cell lines after 4OH treatment induced
FOXO1a-TM-ER
TAM activity. (C) Immunoblot analyses showed that long-term
culture of FOXO1a-TM-ER
TAM–expressing Rh30 cells in a medium contain-
ing tamoxifen selected for cells that lost FOXO1a-TM-ER
TAM expression.
Cells transduced with pBabe were used as the control, and equal loading
of the blot was confirmed by staining with Fast Green dye. (D) FOXO1a-
TM-ER
TAM expression in Rh30-derived tumors in NOD/SCID mice. Rh30-
derived tumors expressing either pBabe vector alone or FOXO1a-TM-ER
TAM
with or without 4OH were stained with an anti-FOXO1a antibody. DAPI
staining was used to calculate the cell number and density. (E) Cell prolifer-
ation was substantially reduced after 4OH treatment in Rh30-derived tu-
mors expressing FoxO1a-TM-ER
TAM
. NOD/SCID mice bearing vector alone
or FOXO1a-TM-ER
TAM–expressing tumors, with or without 4OH treatment,
were injected with BrdU, and tumor sections were stained by indirect
immunofluorescence with an anti-BrdU antibody. DAPI staining was used
to calculate the cell number and density. Bars, 100  m.
Figure 10. FOXO1a activation induces regression of Rh30-derived tumors
in NOD/SCID mice. (A) After 5 wk of growth, NOD/SCID mice bearing
Rh30-derived tumors that expressed vector alone (n   2; closed squares) or
FOXO1a-TM-ER
TAM (n   5; open triangles) were treated with tamoxifen,
and tumor sizes were determined at the indicated intervals after treatment.
FOXO1a-TM-ER
TAM–expressing tumors substantially decreased in size after
tamoxifen treatment, whereas vector-only–expressing tumors continued to
grow. (B) Representative TUNEL assays performed on sections of untreated
Rh30-derived tumors from NOD/SCID mice. DAPI staining was used to cal-
culate cell number and density. (C) Representative TUNEL assay after 9 d of
tamoxifen treatment. Note the increase in the number of TUNEL-positive cells
in tumors expressing FOXO1a-TM-ER
TAM compared with that seen in B. (D)
Active Casp3 in sections of untreated Rh30-derived tumors expressing either
vector only or FoxO1a-TM-ER
TAM in NOD/SCID mice. (E) Active Casp3 in
sections of Rh30-derived tumors after tamoxifen treatment. Note the in-
crease in the number of cells containing active Casp3 in tumors expressing
FOXO1a-TM-ER
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the concept that ARMS and ERMS represent disparate forms
of RMS that arise by independent means and therefore require
different therapeutic strategies to improve outcome.
Restoration of FOXO1a activity blocks the in vitro
growth of all ARMS tumor cell lines tested, a finding consis-
tent with its known role as a regulator of cell proliferation (Ac-
cili and Arden, 2004). In addition, three of four ARMS cell
lines engineered to express FOXO1a underwent rapid and
complete apoptosis, whereas Rh30 ARMS cells displayed total
cell cycle arrest as well as morphological changes reminiscent
of muscle cell differentiation. Restoration of FOXO1a expres-
sion in ARMS directly induces Casp3 transcription, which is
also required for muscle cell differentiation (Fernando et al.,
2002), yet this response also often results in cell death, most
likely because of the transformed nature of ARMS. Thus,
FoxO1a regulates the differentiation of normal early mouse
myoblasts (Bois and Grosveld, 2003; Nishiyama et al., 2004)
and exerts the same role in transformed ARMS cells. Although
different pathways might be switched on or off in t(2;13)
ARMS cell lines, which model secondary tumors, the observa-
tion that all lines are sensitive to FOXO1a suggests that the loss
of this protein is a pivotal step in ARMS tumorigenesis.
These analyses also revealed that ERMS represents a tu-
mor that arises from a progenitor that can express late differen-
tiation markers of muscle cell differentiation, such as MyoHC.
The ERMS phenotype is also associated with the expression of
one or more FOXO proteins, and FOXO1a is necessary for the
muscle cell differentiation program (Bois and Grosveld, 2003;
Nishiyama et al., 2004). In addition, FOXO1a activity appears
to be regulated in ERMS tumors because overexpression of
FOXO1a in ERMS cell lines has no deleterious effects. In par-
ticular, the ability of ERMS cell lines to repress Casp3 is remi-
niscent of the later stages of muscle differentiation (Fernando
et al., 2002). Collectively, these observations underscore the
differences in the oncogenic pathways involved in the estab-
lishment of ARMS and ERMS.
Our results also support the concept that a haploid
FOXO1a gene dose and subsequent or coincidental loss of
FOXO1a protein expression probably cooperate with oncogenic
signals emanating from the PAX3-FOXO1a chimeric transcrip-
tion factor to induce malignant ARMS. Loss of FOXO1a allows
for the bypass of important checkpoints that induce cell cycle ar-
rest (e.g., induction of the cell cycle inhibitor p27
Kip1; Dijkers et
al., 2000; Medema et al., 2000; Kops et al., 2002) or apoptosis
(e.g., induction of caspase-3). Loss of FOXO1a also compro-
mises proper remodeling of the cytoskeleton, which is necessary
for muscle cell fusion and adhesion, both of which have been
linked to the activity of Casp3 (Fernando et al., 2002). Thus, the
differentiation block in ARMS can, at least in part, be attributed
to a loss of the FOXO1a–Casp3 pathway.
Most important, the finding that secondary ARMS tumors,
as modeled by the cell lines used in this study, are sensitive to
FOXO1a expression suggests novel therapeutic opportunities to
fight this deadly disease. Specifically, these findings suggest
that FOXO1a loss of function is an essential event in ARMS tu-
morigenesis and that agents aimed at restoring or augmenting
FOXO1a activity in ARMS cells might be of therapeutic benefit.
Materials and methods
Cell culture
Early passage ARMS and ERMS cell lines (provided by S. Ragsdale and
G. Germain, St. Jude Children’s Research Hospital, Memphis, TN) were
cultured in RPMI growth medium supplemented with 10% FBS. All experi-
ments were performed in this medium. The C2C12 cell line was obtained
from American Type Culture Collection. We used passages 1 and 2 cells
and took particular care to avoid cell overgrowth, which quickly induces
differentiation. C2C12 cells were cultured in DME supplemented with
10% FBS by using standard procedures. Differentiation was then induced
by transferring cells to DME supplemented with 2% horse serum. Primary
myoblasts were isolated from 6-d-old C57Bl/6 mice and cultured as de-
scribed previously (Bois and Grosveld, 2003). Primary tumor samples
were provided by the St. Jude Children’s Research Hospital cell bank.
Real-time RT-PCR, protein, and ChIP analyses
Real-time RT-PCR and Western blotting were performed using standard
protocols (Ausubel et al., 2001). FOXO1a (FKHR), AKT, P-AKT
Thr308,
P-AKT
Ser473, and active caspase-3 antibodies were purchased from Cell Sig-
naling Technology, Inc.; anti–procaspase-3 antibody from BD Biosciences;
anti-AU1 tag from Abcam, Inc.; anti-FOXO3a (FKHRL1) antibody from Up-
state Biotechnology; anti-GFP antibody from Molecular Probes, Inc.; and
anti-FLAG antibody from Sigma-Aldrich. The anti-FOXO4 antibody was
provided by B. Burgering (University Medical Center, Utrecht, Nether-
lands), and the anti-MyoHC MF20 antibody was a gift from D. Fischman
(Weill Medical College of Cornell University, New York, NY). Fast Green
protein dye was purchased from Sigma-Aldrich.
ChIP experiments were performed using the ChIP assay kit (Upstate
Biotechnology) according to the manufacturer’s protocol.
Microscopy and image acquisition
A microscope (BX51; Olympus) fitted with 20 and 40  lenses (Olympus)
was used for imaging. Digital images were acquired using a SPOT RTse
camera and its acquisition software (v4.0.4) for Mac OSX. Subsequent
image processing (cropping, rotating, contrast, and intensity adjust-
ments) was performed using Adobe Photoshop CS (v8.0) for Mac OSX.
DNA was stained with a 10,000 dilution of a DAPI stock solution
(Sigma-Aldrich). Fluorescent secondary antibodies were purchased from
Molecular Probes, Inc.
Luciferase assays
Luciferase reporters carrying the mouse  3.8/ 3.3 or  1.0/ 1.5 kb
caspase-3 promoter regions containing the FoxO1a binding sites as well
as constructs deleted for these sites were generated by inserting PCR-
amplified fragments upstream of the minimal promoter of the pGL3-basic
firefly luciferase vector (Promega). C2C12 myoblasts were transiently
transfected with the promoter–reporter constructs using FuGene6 (Roche
Molecular Systems, Inc.) following the supplier’s protocol. Luciferase de-
tection was performed using the Luciferase Assay System (Promega) as per
the manufacturer’s recommendations. A  -actin promoter–driven secreted
alkaline phosphatase (SEAP) reporter was cotransfected (100 ng per
transfection) to normalize transfection efficiency; SEAP activity was deter-
mined as described previously (Berger et al., 1988). To avoid vector
squelching, we transfected empty MSCV with the reporter construct when
exogenous expression of FoxO1a was not required.
Apoptosis and caspase-3 activity assays
Apoptosis was measured by staining with phycoerythrin-conjugated an-
nexin V according to the manufacturer’s instructions (BD Biosciences).
TUNEL assays were performed using the ApopTag kit (InterGen) as per the
manufacturer’s protocol. To analyze Casp3 activity, we collected floating
cells, combined them with cells growing on the dish, and washed them
twice with PBS. The cells were lysed in caspase lysis buffer (25 mM Hepes-
NaOH, 0.1% sucrose, 1% CHAPS, 2 mM EDTA, and 10 mM dithio-
threitol; pH 7.4). Cell lysates were mixed with caspase assay buffer (25
mM Hepes-NaOH; pH 7.4), 10 mM dithiothreitol, and the fluorogenic
substrate Ac-DEVD-AMC (50  m; caspase-3). After incubation at 37 C for
1 h, the fluorometric detection of released AMC product was performed
on a Fluorescence Multi-well Plate Reader (CytoFluor Series 2350; Milli-
pore) using a 400-nm excitation filter and a 530-nm emission filter.
Virus production, cell transduction, and cell sorting
D. Persons (St. Jude Children’s Research Hospital, Memphis, TN) provided
the MSCV-IRES-GFP vector. M. McMahon (University of California, SanJCB • VOLUME 170 • NUMBER 6 • 2005 912
Francisco, San Francisco, CA) and K. Helin (European Institute of Oncology,
Milan, Italy) provided the pBabe vectors. Dominant-negative FADD cDNA
and AU1 epitope-tagged dominant-negative FADD (NFD-4; a gift from
J.M. Lahti and V.J. Kidd, St. Jude Children’s Research Hospital, Memphis,
TN) were cloned into pMSCV-IRES-GFP. All constructs were generated
using standard molecular biology protocols (Ausubel et al., 2001). Cells
were transduced using standard methods (Ausubel et al., 2001), and after
2–3 d, transduced cells were FACS sorted for GFP expression or were
selected in puromycin-containing medium.
Mice
NOD/SCID mice were purchased from The Jackson Laboratory. Mice were
maintained at St. Jude Children’s Research Hospital under the Institutional
Animal Care and Use Committee guidelines. Generation of xenografted
animals and tamoxifen-sensitive animals was performed as previously
described (Houghton et al., 1995; Hayashi and McMahon, 2002).
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